Potential coronavirus treatment granted rare disease status
Experts who have studied the so-called “orphan drug” program say the company’s request—and the FDA’s decision to grant it—seem inappropriate given the rapidly expanding threat of the viral outbreak. A financial analyst, though, called Gilead’s request “pretty standard.”